Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.
The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results